GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lipigon Pharmaceuticals AB (OSTO:LPGO) » Definitions » Net Income Including Noncontrolling Interests

Lipigon Pharmaceuticals AB (OSTO:LPGO) Net Income Including Noncontrolling Interests : kr-5.29 Mil (TTM As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Lipigon Pharmaceuticals AB Net Income Including Noncontrolling Interests?

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Lipigon Pharmaceuticals AB's Net Income Including Noncontrolling Interests for the three months ended in Dec. 2023 was kr-7.56 Mil. Its Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Dec. 2023 was kr-5.29 Mil.

Lipigon Pharmaceuticals AB Net Income Including Noncontrolling Interests Historical Data

The historical data trend for Lipigon Pharmaceuticals AB's Net Income Including Noncontrolling Interests can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lipigon Pharmaceuticals AB Net Income Including Noncontrolling Interests Chart

Lipigon Pharmaceuticals AB Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Income Including Noncontrolling Interests
Get a 7-Day Free Trial -4.99 -8.07 -41.11 -37.71 -12.13

Lipigon Pharmaceuticals AB Quarterly Data
Dec18 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Jun23 Sep23 Dec23
Net Income Including Noncontrolling Interests Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -6.84 -9.20 7.13 -4.87 -7.56

Lipigon Pharmaceuticals AB Net Income Including Noncontrolling Interests Calculation

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-5.29 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lipigon Pharmaceuticals AB Net Income Including Noncontrolling Interests Related Terms

Thank you for viewing the detailed overview of Lipigon Pharmaceuticals AB's Net Income Including Noncontrolling Interests provided by GuruFocus.com. Please click on the following links to see related term pages.

Lipigon Pharmaceuticals AB (OSTO:LPGO) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lipigon Pharmaceuticals AB (OSTO:LPGO) » Definitions » Net Income Including Noncontrolling Interests
Comparable Companies
OSTO:2CUREX XSAT:ABERA OSTO:EXPRS2 OSTO:SCOL XSAT:CHOSA OSTO:COMBI NGM:COEGIN XSAT:APTA XSAT:DBP B OSTO:CMOTEC B OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
9RP:Germany
Address
Tvistevagen 48 C, Umea, SWE, 90736
Website
https://www.lipigon.se
Lipigon Pharmaceuticals AB develops medicines for diseases caused by disorders of the body's handling of fats. It focuses on orphan drugs for unusual diseases where there is no adequate treatment.

Lipigon Pharmaceuticals AB (OSTO:LPGO) Headlines

No Headlines